英国の臨床栄養市場-2025-2033年

英国の臨床栄養市場は2024年に9億4,093万米ドルに達し、2033年には10億6,955万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは2.4%で成長する見込みです。

臨床栄養製品は、患者の健康維持を助ける医薬品です。ミネラル、ビタミンなどの適切なサプリメントを提供することで、代謝システムの改善に役立ちます。臨床栄養製品は、ミネラル、ビタミン、その他のサプリメントなど適切なサプリメントを提供することで、患者の健康を維持し、身体の代謝システムを改善するのに役立ちます。

英国の臨床栄養市場は、特定の健康ニーズを持つ患者、特に慢性疾患や栄養不良に苦しむ患者に、専門的な栄養サポートや製品を提供することに特化した分野です。この市場には、経腸・非経口栄養ソリューション、医療用食品、栄養補助食品など、さまざまなヘルスケア環境における個人の栄養要件を満たすように設計された多様な製品が含まれます。

臨床栄養学は、食事、栄養と健康上の転帰との関係を検討する分野と定義することができます。臨床栄養学には、さまざまな病状に関連する栄養問題の予防、診断、および管理が含まれます。臨床栄養学の主な目標は、特に病気や治療により従来の食事摂取では不十分な場合に、患者の回復と全体的な健康をサポートするために十分な栄養素を摂取できるようにすることです。こうした要因が、英国の臨床栄養市場の拡大を後押ししています。

市場力学：

促進要因と抑制要因

代謝性疾患の有病率の上昇

英国の臨床栄養市場は、代謝性疾患の有病率の上昇、高いヘルスケア支出、新興国における中間層の増加といった要因によって成長を遂げており、市場の成長を示しています。

肥満、高血圧、インスリン抵抗性、高脂血症などの代謝性疾患の有病率の上昇は、世界的に重大な公衆衛生問題です。これらの疾患は、2型糖尿病、肥満、心血管疾患などの慢性変性疾患と関連しています。代謝障害における栄養の役割はよく研究されていますが、ヒトの代謝や代謝障害に対する作用を実行する栄養素／食品を解明することへの関心はまだ高まっています。

例えば、国際糖尿病連合によると、この地域の成人の糖尿病推計値を作成するために、39カ国からの合計60のデータソースが使用されました。そのデータによると、欧州地域の糖尿病有病率（9.2％）と糖尿病患者数（6,100万人）は、2045年までに13％増加するといいます。欧州地域は、1型糖尿病の小児および青少年の数が最も多く（295,000人）、年間新規発症数も31,000人と最も多いです。

したがって、代謝性疾患やその他の慢性疾患の増加は、予測期間中に市場が成長するのに役立つ臨床栄養の需要を直接増加させます。さらに、健康とウェルネスに対する消費者の注目が高まっていることも、英国の臨床栄養市場の拡大に寄与しています。

臨床栄養に対する認識の欠如

臨床栄養の需要は増加していますが、先進国でも新興諸国でもヘルスケアや食事に関する認識が不足しています。この理解不足は、ビタミンや栄養に関する正しい知識の欠如や誤った情報による欠乏症や障害につながっています。健康と衛生に関する教育や直接的な支援は十分ではないです。さまざまな疾患に対する臨床栄養学の利点について認識を促すキャンペーンが実施されているにもかかわらず、さまざまな疾患に対する臨床栄養学についての理解がまだ不足しており、これが市場の妨げになると予想されます。

しかし、特に新興国における認識不足や厳しい政府規制は、代替栄養手段の採用率を低下させる可能性のあるいくつかの阻害要因です。臨床栄養市場の成長は、栄養摂取のための合理化された手段の拒否や、新しいアプローチの受け入れ不足に起因する生活水準が比較的低い世界の後発開発地域で影響を受ける可能性があります。

健康状態の管理における臨床栄養の意義について、一般市民の間で理解の広範な欠如があります。多くの人々は、栄養がどのように慢性疾患に影響を与えるか、または病気からの回復を助けることができることを認識することができないです。したがって、上記の要因が英国の臨床栄養市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 代謝疾患の有病率の上昇
  • 抑制要因
    • 臨床栄養学に対する認識の欠如
  • 機会
  • 影響分析

第5章 戦略的洞察と業界展望

• 市場のリーダーと先駆者
  • 新たな先駆者と著名なプレーヤー
  • 最大の売上を誇るブランドを確立したリーダー
  • 確立された製品を持つ市場リーダー
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格市場力学
• キーオピニオンリーダー

第6章 製品タイプ別

• 乳児の栄養
• 経腸栄養
• 非経口栄養

第7章 年齢層別

• 成人
• 小児

第8章 投与経路別

• オーラル
• 経腸
• 非経口

第9章 用途別

• 腫瘍学
• 代謝障害
• 胃腸障害
• 神経疾患
• その他

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Abbott Laboratories（Abbott Nutrition）
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Nestle Health Science
• Baxter International Inc
• B. Braun Melsungen AG
• Danone（Nutricia）
• BASF SE
• Perrigo Company PLC
• DSM-Firmenich AG
• AYMES International Ltd
• Nualtra

第13章 付録

The U.K. clinical nutrition market reached US$ 940.93 million in 2024 and is expected to reach US$ 1,069.55 million by 2033, growing at a CAGR of 2.4 % during the forecast period 2025-2033.

Clinical nutrition products are pharmaceutical products that help keep a patient healthy. It helps to improve the metabolic system by providing adequate supplements such as minerals, vitamins, and others. Clinical nutrition products are useful in maintaining the patient's health and improving the body's metabolic system by providing adequate supplements, such as minerals, vitamins, and other supplements.

The clinical nutrition market in the UK is a sector dedicated to providing specialized nutritional support and products for patients with specific health needs, particularly those suffering from chronic diseases or malnutrition. This market includes a diverse range of products such as enteral and parenteral nutrition solutions, medical foods, and dietary supplements that are designed to meet the nutritional requirements of individuals in various healthcare settings.

Clinical nutrition can be defined as the field that examines the relationship between diet, nutrition, and health outcomes. It encompasses the prevention, diagnosis, and management of nutritional issues associated with various medical conditions. The primary goal of clinical nutrition is to ensure that patients receive adequate nutrients to support their recovery and overall health, especially in situations where traditional dietary intake is insufficient due to illness or medical treatment. These factors have driven the U.K. clinical nutrition market expansion.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Metabolic Disorders

The UK clinical nutrition market is experiencing growth due to factors such as rising metabolic disorders prevalence, high healthcare spending, and the rise of the middle class in emerging economies, indicating a growing market.

The rise in the prevalence of metabolic diseases, such as obesity, hypertension, insulin resistance, and hyperlipidemia, is a significant public health issue worldwide. These disorders are associated with chronic degenerative diseases, such as type 2 diabetes, obesity, and cardiovascular disease. The role of nutrition in metabolic disorders is well investigated, but there is still a growing interest in elucidating the nutrients/foods that execute their actions on human metabolism and metabolic disorders.

For instance, according to the International Diabetes Federation, a total of 60 data sources from 39 countries were used to generate diabetes estimates among adults in the region. According to the data, the diabetes prevalence (9.2%) and number of people with diabetes (61 million) in Europe region will increase 13 % by 2045. Europe region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.

Hence, the rise in the number of metabolic disorders and other chronic diseases will increase the demand for clinical nutrition directly which will help the market to grow during the forecast period. Moreover, the increasing focus of consumers on health and wellness contributes to the U.K. clinical nutrition market expansion.

Lack of Awareness for Clinical Nutrition

The demand for clinical nutrition is increasing, but there is a lack of awareness about healthcare and diet in both developed and developing countries. This lack of understanding leads to deficiencies and disorders due to a lack of proper knowledge of vitamins and nutrition, and incorrect information. Education and direct support for health and hygiene are not sufficient. Despite campaigns promoting awareness about clinical nutrition benefits for different diseases, there is still a lack of understanding about clinical nutrition for various illnesses, which is expected to hamper the market.

However, lack of awareness especially in emerging countries, and stringent government regulations are a few of the restraints that may result in lower adoption of alternate means of nutrition. The clinical nutrition market growth can be affected in the least developed regions of the world with comparatively lower standards of living attributed to the refusal of rationalized means to consume nutrition and, lack of acceptance of newer approaches.

There is a widespread lack of understanding among the general public regarding the significance of clinical nutrition in managing health conditions. Many people fail to recognize how nutrition can influence chronic diseases or aid in recovery from illnesses. Thus, the above factors could be limiting the U.K. clinical nutrition market's potential growth.

Segment Analysis

The U.K. clinical nutrition market is segmented based on Product Type, Age Group, route of administration, application, Distribution Channel, and region.

Product Type:

The enteral nutrition segment is expected to dominate the U.K. clinical nutrition market share

The enteral nutrition segment holds a major portion of the U.K. clinical nutrition market share and is expected to continue to hold a significant portion of the U.K. clinical nutrition market share during the forecast period. Enteral nutrition is an essential aspect of healthcare for individuals with a functioning digestive system who are unable to eat or drink. Nestle Health Science, a leader in the field, offers a wide range of enteral feeding products and solutions designed to support various life stages, from pediatrics to healthy aging.

If the gut is working normally to absorb food and nutrients, then Enteral Nutrition is the preferred way of delivering nutritional support. In some patients, enteral nutrition may have to be delivered into the gut through a tube, but in others, it may be possible for them to take this by mouth. This segment has seen substantial growth due to several factors, such as the rising elderly population, the growing incidence of chronic diseases, and a trend towards care being provided in home settings.

Furthermore, major players in the industry key initiatives and expansion of the industry that would propel this segment growth in the U.K. clinical nutrition market. For instance, in October 2022, Galen Medical Nutrition, a subsidiary of Galen Limited, launched TYR EASY Tablets in the UK, marking the first solid-dose protein substitute option for individuals over 8 years old with tyrosinemia. This provides patients with a greater variety of protein substitutes to better suit their individual needs.

Also, in May 2021, Willows Veterinary Centre expanded its clinical nutrition service by launching a specialist-led parenteral nutrition service. Willows is one of the few specialist centers in Europe with a board-certified specialist in clinical nutrition. This service provides intravenous nutrition, including protein, carbohydrates, and fat solutions, to patients when other feeding methods are not possible. These factors have solidified the segment's position in the U.K. clinical nutrition market.

Competitive Landscape

The major global players in the pollinosis market include Abbott Laboratories (Abbott Nutrition), Nestle Health Science, Baxter International Inc, B. Braun Melsungen AG, Danone (Nutricia), BASF SE, Perrigo Company PLC, DSM-Firmenich AG, AYMES International Ltd, and Nualtra among others.

Key developments

• In January 2023, Nutricia, a Danone-owned company, launched its first plant-based medical nutrition drink, Fortimel PlantBased Energy, to address the nutritional needs of individuals who are malnourished or at risk of malnutrition due to illness. This ready-to-drink oral nutritional supplement is made with high-quality plant protein from pea and soy sources, making it suitable for vegans, vegetarians, flexitarians, and those with cow's milk protein allergies. It is designed to match the nutritional profile of the original dairy formula.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The U.K. clinical nutrition market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Application
• 3.5. Snippet by Distribution Channel
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Metabolic Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness for Clinical Nutrition
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest largest-selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Infant Nutrition*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Enteral Nutrition
• 6.4. Parenteral Nutrition

7. By Age Group

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 7.1.2. Market Attractiveness Index, By Age Group
• 7.2. Adult*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pediatric

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Enteral
• 8.4. Parenteral

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Oncology*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Metabolic Disorders
• 9.4. Gastrointestinal Disorders
• 9.5. Neurological Disorders
• 9.6. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Abbott Laboratories (Abbott Nutrition) *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Nestle Health Science
• 12.3. Baxter International Inc
• 12.4. B. Braun Melsungen AG
• 12.5. Danone (Nutricia)
• 12.6. BASF SE
• 12.7. Perrigo Company PLC
• 12.8. DSM-Firmenich AG
• 12.9. AYMES International Ltd
• 12.10. Nualtra

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us